Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer. The findings for each cohort were published today in The Lancet Oncology and The Lancet Diabetes & Endocrinology, respectively.
Vitamins and minerals are micronutrients required by the body to carry out a range of normal functions. However, these micronutrients are not produced in our
Macronutrients hog the spotlight. Everyone is talking about eating the right amount of proteins, fats, and carbohydrates for fitness goals, but there’s another type of
Commercial gyms are closed for at least the next couple of months due to the coronavirus outbreak. As a result, people are left scrambling to
Low testosterone is no joke. Did you know that testosterone levels in men have been on a steady decline since the 1980s? One study found
